Citations

Showing 10 of 108119 citations.

Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma
Ramchandren, Radhakrishnan , Advani, Ranjana H. , Ansell, Stephen M. , Bartlett, Nancy L. , Chen, Robert , Connors, Joseph M. , Feldman, Tatyana , Forero‐Torres, Andres , Friedberg, Jonathan W. , Gopal, Ajay K. , Younes, Anas , Engley, Gerald, Manley, Thomas, Fenton, Keenan , Straus, David J. , Gordon, Leo I , Connors, Joseph M , Bartlett, Nancy L , Advani, Ranjana H , Gopal, Ajay , Gordon, Leo I. , Kuruvilla, John , Savage, Kerry J.

Mayo Clinic

Clinical Cancer Research | January 7, 2019 | Volume: 25 | Issue: 6 | Pages: 1718-1726

10.1158/1078-0432.ccr-18-2435 | PMID 30617130 Get It

Abstract Purpose: To evaluate safety and efficacy outcomes for subjects on the ECHELON-1 study treated in North America (NA). Patients and Methods: ECHELON-1 is a global, open-label, randomized phase III study comparing doxorubicin, vinblastine, and dacarbazine in combination with brentuximab vedotin (A+AVD) versus ABVD (AVD + bleomycin) as first-line therapy in subjects with stage III or IV classical Hodgkin lymphoma (cHL; NCT01712490). Subjects were randomized 1:1 to receive A+AVD or ABVD intravenously on days 1 and 15 of each 28-day cycle for up to 6 cycles. Results: The NA subgroup consisted of 497 subjects in the A+AVD (n = 250) and ABVD (n = 247) arms. Similar to the primary analysis based on the intent-to-treat population, the primary endpoint [modified progression-free survival (PFS) per independent review] demonstrated an improvement among subjects who received A+AVD compared with ABVD (HR = 0.60; P = 0.012). For PFS, the risk of progression or death was also reduced (HR = 0.50; P = 0.002). Subsequent anticancer therapies were lower in the A+AVD arm. Grade 3 or 4 adverse events (AEs) were more common, but there were fewer study discontinuations due to AEs in the A+AVD arm as compared with ABVD. Noted differences between arms included higher rates of febrile neutropenia (20% vs. 9%) and peripheral neuropathy (80% vs. 56%), but lower rates of pulmonary toxicity (3% vs. 10%) in subjects treated with A+AVD versus ABVD. Conclusions: The efficacy benefit and manageable toxicity profile observed in the NA subgroup of ECHELON-1 support A+AVD as a frontline treatment option for patients with stage III or IV cHL.
Somebody Tell Me
Brown, Sherry‐Ann

Mayo Clinic

The Oncologist | January 7, 2019 | Volume: 24 | Issue: 3 | Pages: 423-423

10.1634/theoncologist.2018-0080 | PMID 30617088 Get It

This poem is a reflection on the risk of developing heart disease or cancer, and of the toll of cancer therapy on the heart, written as an inspiration to those working in the fields of oncology and cardiology and those affected by cancer, heart disease, or both.
Integrated Molecular Analysis of Undifferentiated Uterine Sarcomas Reveals Clinically Relevant Molecular Subtypes
Binzer-Panchal, Amrei , Hardell, Elin, Viklund, Björn, Ghaderi, Mehran , Bosse, Tjalling , Nucci, Marisa R. , Hollfelder, Nina , Corcoran, Pádraic, Gonzalez‐Molina, Jordi , Moyano‐Galceran, Lidia , Bell, Debra A., Schoolmeester, John K., Måsbäck, Anna , Kristensen, Gunnar B. , Davidson, Ben , Lehti, Kaisa , Carlson, Joseph W. , Hollfelder, Nina , Gonzalez-Molina, Jordi , Kristensen, Gunnar B , Lehti, Kaisa , Carlson, Joseph W , Lee, Cheng‐Han , Isaksson, Anders

Mayo Clinic

Clinical Cancer Research | January 7, 2019 | Volume: 25 | Issue: 7 | Pages: 2155-2165

10.1158/1078-0432.ccr-18-2792 | PMID 30617134 Get It

Abstract Purpose: Undifferentiated uterine sarcomas (UUS) are rare, extremely deadly, sarcomas with no effective treatment. The goal of this study was to identify novel intrinsic molecular UUS subtypes using integrated clinical, histopathologic, and molecular evaluation of a large, fully annotated, patient cohort. Experimental Design: Fifty cases of UUS with full clinicopathologic annotation were analyzed for gene expression (n = 50), copy-number variation (CNV, n = 40), cell morphometry (n = 39), and protein expression (n = 22). Gene ontology and network enrichment analysis were used to relate over- and underexpressed genes to pathways and further to clinicopathologic and phenotypic findings. Results: Gene expression identified four distinct groups of tumors, which varied in their clinicopathologic parameters. Gene ontology analysis revealed differential activation of pathways related to genital tract development, extracellular matrix (ECM), muscle function, and proliferation. A multivariable, adjusted Cox proportional hazard model demonstrated that RNA group, mitotic index, and hormone receptor expression influence patient overall survival (OS). CNV arrays revealed characteristic chromosomal changes for each group. Morphometry demonstrated that the ECM group, the most aggressive, exhibited a decreased cell density and increased nuclear area. A cell density cutoff of 4,300 tumor cells per mm2 could separate ECM tumors from the remaining cases with a sensitivity of 83% and a specificity of 94%. IHC staining of MMP-14, Collagens 1 and 6, and Fibronectin proteins revealed differential expression of these ECM-related proteins, identifying potential new biomarkers for this aggressive sarcoma subgroup. Conclusions: Molecular evaluation of UUS provides novel insights into the biology, prognosis, phenotype, and possible treatment of these tumors.
Pericardiotomy Enhances Left Ventricular Diastolic Reserve With Volume Loading in Humans
Borlaug, Barry A. , Pochettino, Alberto , Pedrotty, Dawn , Asirvatham, Samuel J. , Carter, Rickey E. , Mauermann, William J., Pedrotty, Dawn M, Abel, Martin D, Asirvatham, Samuel J , Borlaug, Barry A , Carter, Rickey E , Schaff, Hartzell V. , Abel, Martin

Mayo Clinic

Circulation | January 7, 2019 | Volume: 138 | Issue: 20 | Pages: 2295-2297

10.1161/circulationaha.118.036006 | PMID 30571519 Get It

Left Bundle Branch Block Before Transcatheter Aortic Valve Replacement
Gulati, Rajiv , Wang, Andrew , Wang, Andrew

Mayo Clinic

Circulation: Cardiovascular Interventions | January 7, 2019 | Volume: 11 | Issue: 11 | Pages: No page available

10.1161/circinterventions.118.007361 | PMID 30571212 Get It

Time to Go Home, Yet?
Fendler, Timothy J. , Dunlay, Shannon M.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | January 7, 2019 | Volume: 11 | Issue: 11 | Pages: No page available

10.1161/circoutcomes.118.005092 | PMID 30571340 Get It

Periprocedural Stroke and Myocardial Infarction as Risks for Long-Term Mortality in CREST
Jones, Michael R. , Howard, George , Roubin, Gary S., Blackshear, Joseph L., Cutlip, Donald E. , Leimgruber, Pierre P., Prineas, Ronald J. , Lal, Brajesh K. , Voeks, Jenifer H. , Brott, Thomas G. , Investigators, for the CREST, Howard, George , Cohen, David Jonathan , Rhodes, David , Glasser, Stephen P. , Investigators, for the CREST

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | January 7, 2019 | Volume: 11 | Issue: 11 | Pages: No page available

10.1161/circoutcomes.117.004663 | PMID 30571337 Get It

Background: The Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) previously reported increased mortality in patients who sustained a periprocedural stroke or cardiac event (myocardial infarction [MI] or biomarker only) in follow-up to 4 years. We now extend these observations to 10 years. Methods and Results: CREST is a randomized controlled trial designed to compare the outcomes of carotid stenting versus carotid endarterectomy. Proportional hazards models were used to assess the association between mortality and periprocedural stroke, MI, or biomarker-only events. For 10-year follow-up, patients with periprocedural stroke were at 1.74× the risk of death compared with those without stroke (adjusted hazard ratio [HR]=1.74; 95% CI, 1.21–2.50; P <0.003). This increased risk was driven by increased early (between 0 and 90 days) mortality (adjusted HR=14.41; 95% CI, 5.33–38.94; P <0.0001), with no significant increase in late (between 91 days and 10 years) mortality (adjusted HR=1.40; 95% CI, 0.93–2.10; P =0.11). Patients with a protocol MI were at 3.61× increased risk of death compared with those without MI (adjusted HR=3.61; 95% CI, 2.28–5.73; P <0.0001), with an increased hazard both early (adjusted HR=8.20; 95% CI, 1.86–36.2; P =0.006) and late (adjusted HR=3.40; 95% CI, 2.09–5.53; P <0.0001). Patients with a biomarker-only event were at 2.04× increased risk overall (adjusted HR=2.04; 95% CI, 1.09–3.84; P =0.03) than those without MI, with an increased early hazard (adjusted HR=8.44; 95% CI, 1.09–65.5; P =0.04) and a suggestive but nonsignificant association toward higher 91-day to 10-year risk (1.88; 95% CI, 0.97–3.64; P =0.062) contributing to the increased risk. Conclusions: In the CREST trial, patients with periprocedural events demonstrate a substantial increase in future mortality to 10 years. For stroke, this risk is largely confined to an early time frame while periprocedural MI or biomarker-only events confer a continuous increased mortality for 10 years. Strategies to reduce periprocedural events and to optimize the evaluation and management of patients with cardiac events should be considered in efforts to reduce not only early but also long-term mortality. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT00004732.
Safety of Sports for Young Patients With Implantable Cardioverter-Defibrillators
Saarel, Elizabeth V. , Law, Ian H. , Berul, Charles I. , Ackerman, Michael J. , Kanter, Ronald J. , Sanatani, Shubhayan , Berger, Stuart, Fischbach, Peter , Dziura, James , Simone, Laura, Olshansky, Brian , Cannom, David S. , Lampert, Rachel , Sanatani, Shubhayan , Olshansky, Brian , Law, Ian H , Burton, David A., Brandt, Cynthia , Li, Fangyong

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | January 7, 2019 | Volume: 11 | Issue: 11 | Pages: No page available

10.1161/circep.118.006305 | PMID 30520349 Get It

Background: Despite safety concerns, many young patients with implantable cardioverter-defibrillators (ICDs) participate in sports. We undertook a prospective, multinational registry to determine the incidence of serious adverse events because of sports participation. The primary end points were death or resuscitated arrest during sports or injury during sports because of arrhythmia or shock. Secondary end points included system malfunction and incidence of ventricular arrhythmias requiring multiple shocks for termination. Methods: Athletes with ICDs aged ≤21 years were included in this post hoc subanalysis of the ICD Sports Registry. Data on sports and clinical outcomes were obtained by phone interview and medical records review. ICD shocks and clinical details of lead malfunction were classified by 2 electrophysiologists. Results: A total of 129 young athletes participating in competitive (n=117) or dangerous (n=12) sports were enrolled. The mean age was 16 years (range, 10–21; 40% female; 92% white). The most common diagnoses were long QT syndrome (n=49), hypertrophic cardiomyopathy (n=30), and congenital heart disease (n=16). The most common sports were basketball and soccer, including 79 varsity/junior varsity high school and college athletes. During a median follow-up of 42 months, 35 athletes (27%) received 38 shocks. There were no occurrences of death, arrest, or injury related to arrhythmia, during sports. There was 1 ventricular tachycardia/ventricular fibrillation storm during competition. Freedom from lead malfunction was 92.3% at 5 years and 79.6% at 10 years. Conclusions: Although shocks related to competition/practice are not uncommon, there were no serious adverse sequelae. Lead malfunction rates were similar to previously reported in unselected pediatric ICD populations. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT00637754.
Probing the Virtual Proteome to Identify Novel Disease Biomarkers
Smith, J. G. , Melander, Olle , Ngo, Debby , Shaffer, Christian M., Ferguson, Jane F. , Herzig, Matthew , McCarty, Catherine A. , Jarvik, Gail P. , Gordon, Allan , Palmer, Melody R. , Crosslin, David R. , Larson, Eric B. , Pacheco, Jennifer A. , Peissig, Peggy , Brilliant, Murray H. , Kitchner, Terrie, Linneman, James G., Namjou, Bahram , Ritchie, Marylyn D. , Borthwick, Kenneth M., Kiryluk, Krzysztof , Mentch, Frank , Sleiman, Patrick , Karlson, Elizabeth W. , Zhu, Yineng, Denny, Joshua C. , Roden, Dan M. , Gerszten, Robert E. , Wang, Thomas J. , Denny, Joshua C , Jarvik, Gail P , Gordon, Adam S , Pacheco, Jennifer A , Kiryluk, Krzysztof , Ferguson, Jane F , Mosley, Jonathan D , Benson, Mark D. , Chute, Christopher G. , Carrell, David , Kullo, Iftikhar J. , Williams, Marc S , Verma, Shefali S. , Vasan, Ramachandran S. , Yang, Qiong , Roden, Dan M. , Smith, J Gustav

Mayo Clinic

Circulation | January 7, 2019 | Volume: 138 | Issue: 22 | Pages: 2469-2481

10.1161/circulationaha.118.036063 | PMID 30571344 Get It

Background: Proteomic approaches allow measurement of thousands of proteins in a single specimen, which can accelerate biomarker discovery. However, applying these technologies to massive biobanks is not currently feasible because of the practical barriers and costs of implementing such assays at scale. To overcome these challenges, we used a “virtual proteomic” approach, linking genetically predicted protein levels to clinical diagnoses in >40 000 individuals. Methods: We used genome-wide association data from the Framingham Heart Study (n=759) to construct genetic predictors for 1129 plasma protein levels. We validated the genetic predictors for 268 proteins and used them to compute predicted protein levels in 41 288 genotyped individuals in the Electronic Medical Records and Genomics (eMERGE) cohort. We tested associations for each predicted protein with 1128 clinical phenotypes. Lead associations were validated with directly measured protein levels and either low-density lipoprotein cholesterol or subclinical atherosclerosis in the MDCS (Malmö Diet and Cancer Study; n=651). Results: In the virtual proteomic analysis in eMERGE, 55 proteins were associated with 89 distinct diagnoses at a false discovery rate q<0.1. Among these, 13 associations involved lipid (n=7) or atherosclerosis (n=6) phenotypes. We tested each association for validation in MDCS using directly measured protein levels. At Bonferroni-adjusted significance thresholds, levels of apolipoprotein E isoforms were associated with hyperlipidemia, and circulating C-type lectin domain family 1 member B and platelet-derived growth factor receptor-β predicted subclinical atherosclerosis. Odds ratios for carotid atherosclerosis were 1.31 (95% CI, 1.08–1.58; P =0.006) per 1-SD increment in C-type lectin domain family 1 member B and 0.79 (0.66–0.94; P =0.008) per 1-SD increment in platelet-derived growth factor receptor-β. Conclusions: We demonstrate a biomarker discovery paradigm to identify candidate biomarkers of cardiovascular and other diseases.
Trends Over Time in Pap and Pap-HPV Cotesting for Cervical Cancer Screening
MacLaughlin, Kathy L. , Breitkopf, Carmen Radecki , Wilson, Patrick M. , Jacobson, Debra J., Fan, Chun , Sauver, Jennifer L. St. , Jacobson, Robert M. , St Sauver, Jennifer L, St Sauver, Jennifer L , Rutten, Lila J. Finney

Mayo Clinic

Journal of Women's Health | January 7, 2019 | Volume: 28 | Issue: 2 | Pages: 244-249

10.1089/jwh.2018.7380 | PMID 30614380 Get It

Background: In 2012, updated cervical cancer screening recommendations were released with consensus on Papanicolaou (Pap) testing every 3 years for women age 21–65 years or Pap–human papillomavirus (HPV) cotesting at 5-year intervals for women age 30–65 years. Primary study aims: Assess current use of Pap-HPV cotesting and describe local population trends over time in Pap and Pap-HPV cotesting. Secondary aim: Assess sociodemographic factors correlating with screening. Methods: We assessed Rochester Epidemiology Project data for Pap and Pap-HPV cotesting among women age 16 years and older living in Olmsted County, Minnesota, yearly from 2005 (study population n = 47,203) through 2016 (study population n = 49,510). We calculated 3-year (Pap) and 5-year (Pap-HPV) moving prevalence rates of screening as proportion of eligible population. Multivariable logistic regression was used to assess factors potentially associated with screening. Results: In 2016, 64.6% of 27,418 eligible 30- to 65-year-old women were up to date with cervical cancer screening; 60.8% had received Pap-HPV cotest screening. Significant declines in Pap completion rates over time were observed in all age groups, including an unexpected decline in 21- to 29-year-old women. Coincident with decreasing Pap screening rates, Pap-HPV cotesting significantly increased among women age 30–65 years, from 10.0% in 2007 to 60.8% in 2016. Conclusions: This suggests increasing adoption of 2012 screening recommendations in the 30- to 65-year-old population. However, decline in Pap screening among 21- to 29-year-old women is concerning. Disparities by race, ethnicity, smoking status, and comorbidity level were observed. Results suggest need for multilevel patient and clinician interventions to increase cervical cancer screening adherence.